597 related articles for article (PubMed ID: 25169850)
41. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
42. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.
Sato Y
Int J Clin Oncol; 2003 Aug; 8(4):200-6. PubMed ID: 12955574
[TBL] [Abstract][Full Text] [Related]
43. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
44. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
45. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
46. [Neoplasms and angiogenesis].
Lewy-Trenda I
Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
[TBL] [Abstract][Full Text] [Related]
47. Tumor refractoriness to anti-VEGF therapy.
Ribatti D
Oncotarget; 2016 Jul; 7(29):46668-46677. PubMed ID: 27081695
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
49. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
50. Tumour-Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis.
Lopes-Bastos BM; Jiang WG; Cai J
Anticancer Res; 2016 Mar; 36(3):1119-26. PubMed ID: 26977007
[TBL] [Abstract][Full Text] [Related]
51. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
52. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Itatani Y; Kawada K; Yamamoto T; Sakai Y
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
[TBL] [Abstract][Full Text] [Related]
53. III. Angiogenesis: complexity of tumor vasculature and microenvironment.
Furuya M; Yonemitsu Y; Aoki I
Curr Pharm Des; 2009; 15(16):1854-67. PubMed ID: 19519428
[TBL] [Abstract][Full Text] [Related]
54. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
55. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Gacche RN; Meshram RJ
Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
[TBL] [Abstract][Full Text] [Related]
56. VEGF in tumor progression and targeted therapy.
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Curr Cancer Drug Targets; 2013 May; 13(4):423-43. PubMed ID: 23167597
[TBL] [Abstract][Full Text] [Related]
57. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors.
Tavakoli J; Aragon-Ching JB
Anticancer Agents Med Chem; 2010 Oct; 10(8):593-600. PubMed ID: 21182470
[TBL] [Abstract][Full Text] [Related]
59. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
60. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
